205 related articles for article (PubMed ID: 32799597)
1. Clinical Predictive Factors of Response to Treatment in Patients Undergoing Conservative Management of Atypical Endometrial Hyperplasia and Early Endometrial Cancer.
Raffone A; Travaglino A; Flacco ME; Iasevoli M; Mollo A; Guida M; Insabato L; Di Spiezio Sardo A; Carugno J; Zullo F
J Adolesc Young Adult Oncol; 2021 Apr; 10(2):193-201. PubMed ID: 32799597
[No Abstract] [Full Text] [Related]
2. Mismatch repair-deficiency specifically predicts recurrence of atypical endometrial hyperplasia and early endometrial carcinoma after conservative treatment: A multi-center study.
Raffone A; Catena U; Travaglino A; Masciullo V; Spadola S; Della Corte L; Piermattei A; Insabato L; Zannoni GF; Scambia G; Zullo F; Bifulco G; Fanfani F; Di Spiezio Sardo A
Gynecol Oncol; 2021 Jun; 161(3):795-801. PubMed ID: 33812697
[TBL] [Abstract][Full Text] [Related]
3. Dusp6 immunohistochemistry is associated with the response of atypical endometrial hyperplasia and early endometrial cancer to conservative treatment.
Travaglino A; Raffone A; Gencarelli A; Micheli M; Franco L; Zullo F; Mollo A; Di Spiezio Sardo A; Bifulco G; Insabato L
Int J Gynaecol Obstet; 2022 Sep; 158(3):742-747. PubMed ID: 34837386
[TBL] [Abstract][Full Text] [Related]
4. Hysteroscopic Endometrial Focal Resection followed by Levonorgestrel Intrauterine Device Insertion as a Fertility-Sparing Treatment of Atypical Endometrial Hyperplasia and Early Endometrial Cancer: A Retrospective Study.
Giampaolino P; Di Spiezio Sardo A; Mollo A; Raffone A; Travaglino A; Boccellino A; Zizolfi B; Insabato L; Zullo F; De Placido G; Bifulco G
J Minim Invasive Gynecol; 2019; 26(4):648-656. PubMed ID: 30017893
[TBL] [Abstract][Full Text] [Related]
5. Predictive Accuracy of Progesterone Receptor B in Young Women with Atypical Endometrial Hyperplasia and Early Endometrial Cancer Treated with Hysteroscopic Resection plus LNG-IUD Insertion.
Raffone A; Travaglino A; Zullo FM; Gencarelli A; Micheli M; Miranda S; De Franciscis P; Insabato L; Di Spiezio Sardo A; Zullo F; Bifulco G
J Minim Invasive Gynecol; 2021 Jun; 28(6):1244-1253. PubMed ID: 33122144
[TBL] [Abstract][Full Text] [Related]
6. Fertility-preserving treatment outcome in endometrial cancer or atypical hyperplasia patients with polycystic ovary syndrome.
Wang L; Luo X; Wang Q; Lv Q; Wu P; Liu W; Chen X
J Gynecol Oncol; 2021 Sep; 32(5):e70. PubMed ID: 34132069
[TBL] [Abstract][Full Text] [Related]
7. Characteristics of progestin-insensitive early stage endometrial cancer and atypical hyperplasia patients receiving second-line fertility-sparing treatment.
Zhou S; Xu Z; Yang B; Guan J; Shan W; Shi Y; Chen X
J Gynecol Oncol; 2021 Jul; 32(4):e57. PubMed ID: 34085795
[TBL] [Abstract][Full Text] [Related]
8. [Clinical efficacy and pregnancy outcomes of fertility-preserving re-treatment after recurrence of the patient with atypical endometrial hyperplasia and early stage endometrial carcinoma].
He YJ; Wang YQ; Tang HR; He M; Rao Y; Zhou R; Wang JL
Zhonghua Fu Chan Ke Za Zhi; 2020 Jan; 55(1):21-28. PubMed ID: 32074769
[No Abstract] [Full Text] [Related]
9. Conservative re-treatment of women with atypical endometrial hyperplasia and early endometrial carcinoma: We can hope, at least.
Raffone A; Raimondo D; Rovero G; Travaglino A; Lopez G; Di Maio CM; Neola D; Raspollini A; Renzulli F; Filippelli A; Casadio P; Seracchioli R; Guida M
Int J Gynaecol Obstet; 2024 May; 165(2):542-551. PubMed ID: 37772342
[TBL] [Abstract][Full Text] [Related]
10. Metformin plus megestrol acetate compared with megestrol acetate alone as fertility-sparing treatment in patients with atypical endometrial hyperplasia and well-differentiated endometrial cancer: a randomised controlled trial.
Yang BY; Gulinazi Y; Du Y; Ning CC; Cheng YL; Shan WW; Luo XZ; Zhang HW; Zhu Q; Ma FH; Liu J; Sun L; Yu M; Guan J; Chen XJ
BJOG; 2020 Jun; 127(7):848-857. PubMed ID: 31961463
[TBL] [Abstract][Full Text] [Related]
11. Diabetes mellitus and responsiveness of endometrial hyperplasia and early endometrial cancer to conservative treatment.
Raffone A; Travaglino A; Saccone G; Di Maio A; Mollo A; Mascolo M; De Rosa R; De Placido G; Insabato L; Zullo F
Gynecol Endocrinol; 2019 Nov; 35(11):932-937. PubMed ID: 31165649
[No Abstract] [Full Text] [Related]
12. RNA-seq and ATAC-seq analysis of CD163
Wang L; Lv Q; Wu P; Luo S; Liu S; Chen X; Luo X
Cancer Med; 2023 Mar; 12(5):5964-5978. PubMed ID: 36373483
[TBL] [Abstract][Full Text] [Related]
13. Effects of hysteroscopic surgery combined with progesterone therapy on fertility and prognosis in patients with early endometrial cancer and atypical endometrial hyperplasia or endometrial intraepithelial neoplasia: a meta-analysis.
Ye X; Li T
Arch Gynecol Obstet; 2024 Jan; 309(1):259-268. PubMed ID: 37540307
[TBL] [Abstract][Full Text] [Related]
14. Hysteroscopic Curettage Followed by Megestrol Acetate Plus Metformin as a Fertility-Sparing Treatment for Women with Atypical Endometrial Hyperplasia or Well-Differentiated Endometrioid Endometrial Carcinoma.
Jing CY; Li SN; Shan BE; Zhang W; Tian WJ; Ren YL; Wang HY
Clin Med Insights Oncol; 2022; 16():11795549221110522. PubMed ID: 35875417
[TBL] [Abstract][Full Text] [Related]
15. Prognosis of patients with endometrial cancer or atypical endometrial hyperplasia after complete remission with fertility-sparing therapy.
Ga H; Taguchi A; Honjoh H; Nishijima A; Eguchi S; Miyamoto Y; Sone K; Mori M; Osuga Y
Arch Gynecol Obstet; 2023 Nov; 308(5):1629-1634. PubMed ID: 37310452
[TBL] [Abstract][Full Text] [Related]
16. PPOS Protocol Effectively Improves the IVF Outcome Without Increasing the Recurrence Rate in Early Endometrioid Endometrial Cancer and Atypical Endometrial Hyperplasia Patients After Fertility Preserving Treatment.
Chen J; Cheng Y; Fu W; Peng X; Sun X; Chen H; Chen X; Yu M
Front Med (Lausanne); 2021; 8():581927. PubMed ID: 34386503
[No Abstract] [Full Text] [Related]
17. [Analysis of pregnancy outcome after fertility-preserving treatment among women with atypical endometrial hyperplasia or endometrial carcinoma].
Xiao ZR; Lu Q; Zhou R; Wang YQ; Liang WY; Liu HX; Tang HR; Wu GZ; Liu XS; Zhang H; Ren Y; Wang JL
Zhonghua Fu Chan Ke Za Zhi; 2020 Dec; 55(12):857-864. PubMed ID: 33355761
[No Abstract] [Full Text] [Related]
18. [GnRH-a combined fertility-sparing re-treatment in women with endometrial carcinoma or atypical endomertial hyperplasia who failed to oral progestin therapy].
Chen JY; Cao DY; Zhou HM; Yu M; Yang JX; Wang JH; Zhang Y; Cheng NH; Peng P
Zhonghua Fu Chan Ke Za Zhi; 2021 Aug; 56(8):561-568. PubMed ID: 34420288
[No Abstract] [Full Text] [Related]
19. Should progesterone and estrogen receptors be assessed for predicting the response to conservative treatment of endometrial hyperplasia and cancer? A systematic review and meta-analysis.
Raffone A; Travaglino A; Saccone G; Mollo A; De Placido G; Insabato L; Zullo F
Acta Obstet Gynecol Scand; 2019 Aug; 98(8):976-987. PubMed ID: 30779338
[TBL] [Abstract][Full Text] [Related]
20. Is repeated high-dose medroxyprogesterone acetate (MPA) therapy permissible for patients with early stage endometrial cancer or atypical endometrial hyperplasia who desire preserving fertility?
Yamagami W; Susumu N; Makabe T; Sakai K; Nomura H; Kataoka F; Hirasawa A; Banno K; Aoki D
J Gynecol Oncol; 2018 Mar; 29(2):e21. PubMed ID: 29400014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
